Roth Mkm Begins Coverage on Longeveron (NASDAQ:LGVN)

Research analysts at Roth Mkm started coverage on shares of Longeveron (NASDAQ:LGVN) in a report issued on Friday, Marketbeat.com reports. The firm set a “buy” rating and a $10.00 price target on the stock. Roth Mkm’s price target would suggest a potential upside of 380.77% from the company’s current price.

Several other analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Longeveron in a report on Monday, November 25th. Maxim Group dropped their target price on Longeveron from $15.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 27th.

Longeveron Stock Performance

Shares of LGVN opened at $2.08 on Friday. Longeveron has a one year low of $0.77 and a one year high of $23.90. The stock has a market capitalization of $30.87 million, a price-to-earnings ratio of -0.33 and a beta of 0.31. The stock has a 50 day moving average price of $2.02 and a 200 day moving average price of $2.17.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.19. Longeveron had a negative return on equity of 142.43% and a negative net margin of 967.49%. The firm had revenue of $0.77 million during the quarter, compared to analysts’ expectations of $0.34 million. During the same period in the previous year, the business earned ($2.80) earnings per share. On average, analysts predict that Longeveron will post -3.47 earnings per share for the current year.

Institutional Trading of Longeveron

Several large investors have recently added to or reduced their stakes in the stock. State Street Corp acquired a new position in shares of Longeveron in the 3rd quarter valued at $29,000. Geode Capital Management LLC lifted its stake in shares of Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after purchasing an additional 97,953 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Longeveron in the 2nd quarter valued at $236,000. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.